In these results presented at ASH-2019, a high number of positive objective responses (OR) were reported, in 6 of 8 evaluable patients (75% OR): of these, there were 2 complete remissions (CR), 3 complete remissions with incomplete hematologic recovery (CRi) and 1 partial remission (PR). The average follow-up time among evaluable patients was 20 weeks, with an average time to response (TTR) of only 32 days in those patients who responded. Two of the 5 patients (40%) who had received more than 3 treatment cycles had also become transfusion independent (that is, they did not require periodic red blood cell transfusions). The company plans to provide a new update of the results of this study at the
ALICE is a single-arm Phase II study that evaluates the safety and clinical efficacy of iadademstat in combination with standard of care azacitidine in newly diagnosed elderly AML patients, who are not eligible for conventional therapy. The study is being carried out in several Spanish hospitals. Oryzon's commitment to rare diseases is not limited only to the cancer field but also expands to neurological diseases. Thus, the company is beginning the evaluation of the potential of its drug vafidemstat, a CNS-optimized LSD1 inhibitor, as a therapeutic alternative in rare genetic variants of autism and schizophrenia. These possibilities have recently been raised by several independent studies of prestigious American Universities that have shown the efficacy of Oryzon LSD1 inhibitors in various experimental models of these genetic subvariants, which could represent a precision medicine approach in the psychiatric field that would be the first of its kind.
About Oryzon
Founded in 2000 in
FORWARD-LOOKING STATEMENTS
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comision Nacional del
Contact:
Tel: +41 79 598 7149
Email: hherklots@lifesciadvisors.com
(C) 2020 Electronic News Publishing, source